<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="H6E32A076271441628130085722DC6E06" public-private="public">
	<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>114 HR 2623 IH: Personal Drug Importation Fairness Act of 2015</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2015-06-03</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">I</distribution-code>
		<congress>114th CONGRESS</congress>
		<session>1st Session</session>
		<legis-num>H. R. 2623</legis-num>
		<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber>
		<action>
			<action-date date="20150603">June 3, 2015</action-date>
			<action-desc><sponsor name-id="E000288">Mr. Ellison</sponsor> (for himself, <cosponsor name-id="R000409">Mr. Rohrabacher</cosponsor>, <cosponsor name-id="S001145">Ms. Schakowsky</cosponsor>, and <cosponsor name-id="G000551">Mr. Grijalva</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To reduce prescription drug costs by allowing the importation and reimportation of certain drugs.</official-title>
	</form>
	<legis-body id="H8FCB84DE58D04CBEAB200CFF4F20C7EC" style="OLC">
 <section id="H7ABC5B164D41497F9E7F2C00BE01A0DD" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Personal Drug Importation Fairness Act of 2015</short-title></quote>.</text> </section><section id="HF2C197CF61E34453B0987251829ABF5D"><enum>2.</enum><header>Reducing prescription drug costs by allowing certain drugs to be imported or reimported</header> <subsection id="HF710A772B0564567A654C164707BBA05"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Notwithstanding any provision of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/301">21 U.S.C. 301 et seq.</external-xref>), a drug may be imported into the United States, and may be reimported into the United States by a person other than the drug’s manufacturer, if the drug—</text>
 <paragraph id="H88207188219947D7BD8FD68D4270CE9D"><enum>(1)</enum><text>has the same active ingredients, route of administration, and strength as a prescription drug approved under chapter V of such Act (<external-xref legal-doc="usc" parsable-cite="usc/21/351">21 U.S.C. 351 et seq.</external-xref>);</text>
 </paragraph><paragraph id="H1B4C16E79670429DA03C9C1ED6AD0191"><enum>(2)</enum><text>may be lawfully marketed in, and is imported or reimported from, a qualified country;</text> </paragraph><paragraph id="HDDF7ADF906494F538C8BA4B539C7913F"><enum>(3)</enum><text>is dispensed by a licensed pharmacist;</text>
 </paragraph><paragraph id="HF5615DF4408D4E9F8E93A00BD7B6F070"><enum>(4)</enum><text>is shipped directly to, or is imported by, the ultimate consumer from the qualified country;</text> </paragraph><paragraph id="H31AD121E33364D5D91CAF06E397209CF"><enum>(5)</enum><text>is shipped or imported in quantities that do not exceed a 90-day supply; and</text>
 </paragraph><paragraph id="H94FC414A38BE43AF87F641C9315DECDB"><enum>(6)</enum><text>is accompanied by a copy of a valid prescription.</text> </paragraph></subsection><subsection id="HCD1DA36684624BCF8DB46E05D9F7B585"><enum>(b)</enum><header>Definitions</header><text display-inline="yes-display-inline">In this Act:</text>
 <paragraph id="H290EB2E6A6FD4226901CF6C593158A08"><enum>(1)</enum><text>The term <term>drug</term> has the meaning given to such term in section 201 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/321">21 U.S.C. 321</external-xref>), except that such term excludes any controlled substance (as defined in section 102 of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/802">21 U.S.C. 802</external-xref>)).</text>
 </paragraph><paragraph id="H1F7F4F0D110A4B40B9B7A2E96805ED6D"><enum>(2)</enum><text>The term <term>prescription drug</term> means a drug subject to section 503(b)(1) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/353">21 U.S.C. 353(b)(1)</external-xref>).</text>
 </paragraph><paragraph id="H5652FD76574D437496DF69472F5091A9"><enum>(3)</enum><text display-inline="yes-display-inline">The term <term>qualified country</term> means a country that—</text> <subparagraph id="H3AE0D8D4081546CBA70F8455BC13E4F9"><enum>(A)</enum><text>is Australia, Canada, Israel, Japan, New Zealand, Switzerland, South Africa, a member-state of the European Union, or a country in the European Economic Area; and</text>
 </subparagraph><subparagraph id="H869BF6641A374BD295E28F5FDB9673B0"><enum>(B)</enum><text>is determined by the Commissioner of Food and Drugs to have standards for ensuring the safety and effectiveness of drugs that are at least as protective as such standards in the United States.</text>
					</subparagraph></paragraph></subsection></section></legis-body>
</bill>


